Follow-up Assessment: Complicated Treatment Decisions in NSCLC
Hematology-Oncology
Launch Date:
April 03, 2018
April 03, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Relevant Terms:
Oncology, NSCLC, Hematology
| 1. | Assess the most current safety and efficacy data and guideline recommendations associated with evidence-based targeted therapies | 2. | Select the most appropriate patients for anti-VEGF therapy based on individualized characteristics, comorbidities, risk factors, and current clinical evidence |
| 3. | Identify the role of novel immunotherapies in the use of individualized targeted therapies for advanced NSCLC | 4. | Incorporate updated genomic testing guidelines and streamlined algorithms for evidence-based targeted treatments of NSCLC patients |
| 1. | Assess the most current safety and efficacy data and guideline recommendations associated with evidence-based targeted therapies |
| 2. | Select the most appropriate patients for anti-VEGF therapy based on individualized characteristics, comorbidities, risk factors, and current clinical evidence |
| 3. | Identify the role of novel immunotherapies in the use of individualized targeted therapies for advanced NSCLC |
| 4. | Incorporate updated genomic testing guidelines and streamlined algorithms for evidence-based targeted treatments of NSCLC patients |
You are receiving this follow-up because you participated in the "Expert Panel Discussion: Complicated Treatment Decisions in NSCLC" activity. Please proceed.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
